Evidence map›Paper›PMID 40454869›Full record

Trial reportAmerican journal of respiratory and critical care medicine2025

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One

Claire Wainwright, Susanna A McColley, Paul McNally, Michael Powers, Felix Ratjen, Jonathan H Rayment, George Retsch-Bogart, Erica Roesch, Bonnie Ramsey, Edward F McKone and 8 more

Abstract readClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Claire WainwrightQueensland Children's Hospital, South Brisbane, Queensland, Australia.
Susanna A McColleyFeinberg School of Medicine, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Paul McNallyRSCI University of Medicine and Health Sciences, Dublin, Ireland.ORCID 0000-0001-7102-1712
Michael PowersOregon Health & Sciences University, Portland, Oregon.
Felix RatjenUniversity of Toronto, Toronto, Ontario, Canada.
Jonathan H RaymentBC Children's Hospital, Vancouver, British Columbia, Canada.
George Retsch-BogartUniversity of North Carolina, Chapel Hill, North Carolina.
Erica RoeschUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio.
Bonnie RamseySeattle Children's Hospital, Seattle, Washington.
Edward F McKoneSt. Vincent's University Hospital, Dublin, Ireland.ORCID 0000-0002-5455-8208
Elizabeth TullisSt. Michael's Hospital, Toronto, Ontario, Canada.
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-4057-2199
Jennifer L Taylor-CousarNational Jewish Health, Denver, Colorado.ORCID 0000-0002-5436-9722
David WaltzVertex Pharmaceuticals, Inc., Boston, Massachusetts; and.
Neil AhluwaliaVertex Pharmaceuticals, Inc., Boston, Massachusetts; and.
Chenghao ChuVertex Pharmaceuticals, Inc., Boston, Massachusetts; and.
Christina V SciricaVertex Pharmaceuticals, Inc., Boston, Massachusetts; and.
Jane C DaviesNational Heart & Lung Institute, Imperial College London and Royal Brompton Hospital, London, United Kingdom.

Funding

Vertex Pharmaceuticals
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cystic FibrosisQuinolinesAllelesAminophenolsBenzodioxolesChildChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsFemaleHumansIndolesMalePyrazolesPyridinesTreatment OutcomeAminophenolsBenzodioxolesChloride Channel AgonistsCystic Fibrosis Transmembrane Conductance RegulatorDrug Combinationselexacaftor, ivacaftor, tezacaftor drug combinationIndolesPyrazolesPyridinesQuinolineschildrencystic fibrosis transmembrane conductance regulator modulatorelexacaftor/tezacaftor/ivacaftorlong-term extension study

Identifiers

PMID40454869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.